Company intelligence / Profile preview

DeepVax

Zürich, Zürich, Switzerland

Ownership: Private
Development stage: Other

Overview

DeepVax's VLP-based vaccine platform has achieved encouraging proof-of-concept in preclinical models for several chronic diseases, oncology, and allergy, and has advanced multiple major programs toward clinical trial application with external validation by third-party licensing agreements[3][4].

Therapeutic areas: ImmunologyEndocrinologyPulmonologyOtherDermatologyOncology
Modalities: VaccineVirus-like particleBiologic
Industry: Biotech

Partnerships

Allergy TherapeuticsSaiba AG

Beyond the preview

Go deeper on DeepVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeepVax.

Explore the full profile